Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 285-296

  Clarke, S J ^a,b   Farrugia, D C ^a   Aherne, G W ^a   Pritchard, D M ^a,c   Benstead, J ^a,d   Jackman, A L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b SYDNEY CANCER CENTRE   (Australia)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYURIDINE; FOLIC ACID; FOLIC ACID ANTAGONIST; RALTITREXED; THYMIDINE; THYMIDYLATE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG INDICATION; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; INTESTINE VILLUS ATROPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYURIDINE; DIARRHEA; DIGESTIVE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID; INTESTINAL MUCOSA; INTESTINE, LARGE; INTESTINE, SMALL; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; QUINAZOLINES; THIOPHENES; THYMIDINE; THYMIDYLATE SYNTHASE; WEIGHT LOSS;

EID: 0033956631     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., Judson, I. R., and Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 57: 5579-5586, 1991.
2. Jackman, A. L., Farrugia, D. C., Gibson, W., Kimbell, R., Harrap, K. R., Stephens, T. C., Azab, M., and Boyle, F. T. Z. D1694 (Tomudex). A new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer, 31A: 1277-1282, 1995.
3. Jackman, A. L., Boyle, F. T., and Harrap, K. R. Tomudex (ZD1694). From concept to care, a programme in rational drug discovery. Investig. New Drugs, 14: 305-316, 1996.
4. Hughes, L. R., Stephens, T. C., Boyle, F. T., and Jackman, A. L. RTX (Tomudex), a highly polyglutamatable antifolate thymidylate synthase inhibitor:design and preclinical activity. In: A. L. Jackman (ed.), Antifolate Drugs in Cancer Therapy, pp. 147-165. Totowa, NJ: Humana Press, 1999.
5. Beale, P., and Clarke, S., Tomudex. Clinical development. In: A. L. Jackman (ed.), Antifolate Drugs in Cancer Therapy, pp. 167-181. Totowa, NJ: Humana Press, 1999.
6. Clarke, S. J., Hanwell, J., de Boer, M., Planting, A., Verweij, J., Walker, M., Smith, R., Jackman, A. L., Hughes, L. R., Harrap, K. R., Kennealey, G. T., and Judson, I. R. Phase I trial of ZD1694 (Tomudex), a new folate based, thymidylate synthase inhibitor. J. Clin. Oncol., 14: 1496-1503, 1996.
7. Zalcberg, J. R., Cunningham, D., Van Custem, E., Francois, E., Schornagel, J. H., Adenis, A., Green, M., Iveson, A., Azab, M., and Seymour, L. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Oncol., 14: 716-721, 1996.
8. Cunningham, D. Mature results from three large controlled studies with RTX (Tomudex). Br. J. Cancer, 77 (Suppl. 2): 15-21, 1998.
9. Cunningham, D., Zalcberg, J. R., Rath, U., Olver, I., Van Cutsem, E., Svensson, C., Seitz, J. F., Harper, P., Kerr, D., Perez-Manga, G., Azab, M., Seymoor, L., Lowery, K., and the "Tomudex" Colorectal Cancer Study Group. Tomudex (ZD1694). Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur. J. Cancer, 31A: 1945-1954, 1995.
10. Maughan, T. S., James, R. D., Kerr, D., McArdle, C., Ledermann, J. A., Seymour, M., Johnston, C., and Stephens, R. J. Preliminary results of a multicentre randomized trial comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 262, 1999.
11. 10-substituted 5,8-dideazafolates. Adv. Enzyme Regul., 31: 13-27, 1991.
12. Jackman, A. L., Gibson, W., Brown, M., Kimbell, R., and Boyle, F. T. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICT D1694. in: Y. Rustum (ed.), Proceedings of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumours: Laboratory and Clinical Correlation. Advances in Experimental Medicine and Biology, Vol. 339, pp. 265-276. New York: Plenum Publishing Corp., 1993.
13. Gibson, W., Bisset, G., Marsham, P. R., Kelland, L. R., Judson, I. R., and Jackman, A. L. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. Biochem. Pharmacol., 45: 863-869, 1993.
14. Aherne, G. W., Ward, E., Lawrence, N., Dobinson, D., Clarke, S. J., Musgrove, H., Sutcliffe, F., Stephens, T., and Jackman, A. L. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor in preclinical models. Br. J. Cancer, 77: 221-226, 1998.
15. Aherne, W., Hardcastle, A., Kelland, L., and Jackman, A. The measurement of deoxynucleotide (dNTP) pools by radioimmunoassay. In: A. Sahota and M. Taylor (eds.), Purine and Pyrimidine Metabolism in Man. VIII. Advances in Experimental Medicine and Biology, Vol. 370, pp. 801-804. New York: Plenum Publishing Corp., 1995.
16. Aherne, G. W., Hardcastle, A., Raynaud, F., and Jackman, A. L. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase: effect of Tomudex (ZD 1694) and nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukemia cells. Biochem. Pharmacol., 51: 1293-1301, 1996.
17. Skelton, L. A., Ormerod, M. G., Tiitley, J., and Jackman, A. L. Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. Cytometry, 33: 56-66, 1998.
18. Tonkinson, J. L., Marder, P., Addis, S. L., Schultz, R. M., Gossett, L. S., Shih, C., and Mendelsohn, L. Cell cycle effects of antifolate antimetabolites implications for cytotoxicity and cytostasis. Cancer Chemother. Pharmacol., 39: 521-532, 1997.
19. Aherne, G. W., and Brown, S. The role of uracil misincorporation in thymineless death. In: A. L. Jackman (ed.), Antifolate Drugs in Cancer Therapy, pp. 409-421. Totowa, NJ: Humana Press, 1999.
20. Curtin, N. J., Harris, A. L., and Aherne, G. W. Mechanism of cell death following TS inhibition: 2′deoxyuridine-5′-triphosphate accumulation, DNA damage and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res., 51: 2346-2352, 1991.
21. Cadman, C. E., Lawrence, T. S., Shewach, D. S., Tany, H-Y., and Maybaum, J. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate. Cancer Res., 53: 5219-5224, 1993.
22. Chu, E., Ju, J., and Schmitz, J. C. Molecular regulation of expression of thymidylate synthase. In: A. L. Jackman (ed.), Antifolate Drugs in Cancer Therapy, pp. 397-408. Totowa. NJ: Humana Press, 1999.
23. Pritchard, D. M., Potten, C. C. S., and Hickman, J. A. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res., 58: 5453-5465, 1998.
24. Houghton, P. J., Thymineless death. In: A. L. Jackman (ed.), Antifolate Drugs in Cancer Therapy, pp. 423-435. Totowa, NJ: Humana Press, 1999.
25. Taylor, G. A., Dady, P. J., and Harrap, K. R. Quantitative high-performance liquid chromatography of nucleosides and bases in human plasma. J. Chromatogr., 183: 421-431, 1980.
26. Taylor, G. A., Jackman, A. L., Calvert, A. H., and Harrap, K. R. Plasma nucleoside and base levels following treatment with the new thymidylate synthase inhibitor CB3717. In: C. H. M. M. De Bruyn (ed.), Purine Metabolism in Man-IV, pp. 379-382. New York: Plenum Publishing Corp., 1984.
27. Jackman, A. L., Taylor, G. A., Calvert, A. H., and Harrap, K. R. Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB 3717. Biochem. Pharmacol., 33: 3269-3275, 1984.
28. Pressacio, J., Mitrovski, B., Erlichman, C., and Medley, D. W. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res., 55: 1505-1508, 1995.
29. Smith, G. K., Bigley, J. W., Dev, I. K., Duch, D. S., Ferone, R., and Pendergast, W. GW1843. A potent, noncompetitive thymidylate synthase inhibitor-preclinical and preliminary clinical studies. In: A. L. Jackman (ed.), Antifolate Drugs in Cancer Therapy, pp. 203-227. Totowa, NJ: Humana Press, 1999.
30. Pritchard, D. M., and Hickman, J. A. Genetic determinants of cell death and toxicity. In: A. L. Jackman (ed.), Antifolate Drugs in Cancer Therapy, pp. 437-451. Totowa, NJ: Humana Press, 1999.
31. Potten, C. S., and Grant, H. K., The relationship between ionising radiation-induced apoptosis and stem cells in the small and large intestine. Br. J. Cancer, 78: 993-1003, 1998.